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Abstract
Interferon-induced BST2/Tetherin prevents budding of vpu-deficient HIV-1 by tethering mature viral particles to the plasma
membrane. BST2 also inhibits release of other enveloped viruses including Ebola virus and Kaposi’s sarcoma associated
herpesvirus (KSHV), indicating that BST2 is a broadly acting antiviral host protein. Unexpectedly however, recovery of
human cytomegalovirus (HCMV) from supernatants of BST2-expressing human fibroblasts was increased rather than
decreased. Furthermore, BST2 seemed to enhance viral entry into cells since more virion proteins were released into BST2-
expressing cells and subsequent viral gene expression was elevated. A significant increase in viral entry was also observed
upon induction of endogenous BST2 during differentiation of the pro-monocytic cell line THP-1. Moreover, treatment of
primary human monocytes with siRNA to BST2 reduced HCMV infection, suggesting that BST2 facilitates entry of HCMV into
cells expressing high levels of BST2 either constitutively or in response to exogenous stimuli. Since BST2 is present in HCMV
particles we propose that HCMV entry is enhanced via a reverse-tethering mechanism with BST2 in the viral envelope
interacting with BST2 in the target cell membrane. Our data suggest that HCMV not only counteracts the well-established
function of BST2 as inhibitor of viral egress but also employs this anti-viral protein to gain entry into BST2-expressing
hematopoietic cells, a process that might play a role in hematogenous dissemination of HCMV.
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Introduction
Human cytomegalovirus (HCMV), a b-herpesvirus, maintains a
lifelong, asymptomatic infection in immunocompetent hosts but is
an opportunistic pathogen in immunocompromised individuals
[1,2]. HCMV is also the leading infectious cause of congenital
birth defects in neonates [3]. Moreover, in post-transplant patients
HCMV is capable of causing disseminated disease in most organs
and tissue types [4,5,6]. Thus, HCMV is able to infect a wide
range of host cells. However, the host factors required for viral
entry into different cell types are incompletely understood. Initially
the virus attaches to heparan sulphate proteoglycans, followed by
virion surface glycoproteins interacting with their cellular
receptors that include integrins and the EGF receptor along with
other as yet undefined molecules in cholesterol rich membrane
micro-domains [7]. The two known pathways of HCMV entry are
fusion with the plasma membrane and endocytosis. The respective
pathway used is dependent on the cell type and viral glycoprotein
composition [8,9]. The role of cellular receptors in each of these
processes is largely unknown, and it is likely that yet to be
identified cellular proteins will be involved in viral entry processes.
BST2 (Bone marrow stromal cell antigen 2) was initially thought
to be involved in normal and malignant B cell differentiation since
this protein is expressed on bone marrow stromal cells and
multiple myeloma cells [10]. However, the murine homologue was
later shown to be highly expressed by plasmacytoid dendritic cells
suggesting a role in innate immunity. Moreover, it was shown that
BST2 is an IFN inducible protein that can act as a ligand to ILT7,
a receptor on dendritic cells that modulates IFN production
[11,12]. The first indication that BST2 might be involved in the
host defense against viruses was implied by our finding that BST2
was downregulated by the immune evasion molecule K5/MIR2, a
transmembrane E3 ubiquitin ligase of Kaposi’s sarcoma associated
herpesvirus (KSHV) that targets multiple host cell immunorecep-
tors for destruction via ubiquitination [13,14]. Subsequently, it was
demonstrated that BST2 represented the interferon-induced host
cell factor responsible for preventing release of HIV-1 lacking
Vpu, [15,16,17]. Prior to this work, Vpu was known to eliminate
CD4 and MHC-I via ubiquitin-mediated processes [18]. Based on
this finding, many unrelated enveloped viruses were recently
shown to be restricted by BST2, including the a-retrovirus RSV,
the b-retroviruses MPMV and HERV-K, the d-retrovirus HTLV-
1, the spumaretrovirus PFV, the filoviruses Marburg and Ebola,
the arenavirus Lassa, non-human primate retro viruses, and the
endogenous b-retroviruses of sheep enJSRV [19,20,21,22]. In
addition to K5 and Vpu, several BST2-antagonists were
discovered in other viruses, including HIV-2 Env, simian
immunodeficiency virus (SIVmac/smm) Nef, SIVtan Env, and Ebola
GP [17,19,21,23,24].
BST2 is a heavily glycosylated, type II transmembrane protein.
It has a short cytoplasmic N-terminal region, a transmembrane
region, a coiled coil extracellular domain and a C-terminal
glycosylphosphatidylinisotol (GPI) anchor [25]. This topology of
BST2 with a transmembrane domain and a GPI anchor is rather
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prion protein [25,26]. BST2 forms intermolecular disulfide bridges
with conserved extracellular cysteines in the coiled-coil domain
[27]. It was further suggested that BST2 forms a picket fence-like
structure having its transmembrane domain located on the
periphery and the GPI anchor inside the lipid raft [25]. This
flexible structure of BST2 is thought to be important for
preventing virions from budding by retaining the transmembrane
domain in the cell membrane and the GPI anchor incorporated
into the virion during the budding process [28].
Here, we examine whether BST2 restricts HCMV release. We
report the surprising observation that increased titers of HCMV
are obtained from supernatants of BST2-expressing fibroblasts, a
finding that is in stark contrast to observations reported to date for
all other viruses implying that HCMV efficiently overcomes any
anti-viral function of BST2. On closer inspection, we found that
increased viral release was a downstream effect of BST2
enhancing viral entry and thereby HCMV gene expression and
replication. A potential role for BST2-mediated HCMV entry in
viral pathogenesis and dissemination is suggested by the finding
that BST2 enhances entry of HCMV into monocytes that
constitutively express high levels of BST2. Our data thus suggest
that HCMV uses this IFN-induced anti-viral protein to increase
infection of monocytic cells, which play a central role in HCMV
latency, reactivation and dissemination.
Results
BST2 enhances virus infection
To examine whether the ability of BST2/Tetherin to prevent
release of a wide spectrum of enveloped viruses would extend to
HCMV, we examined the supernatant of HCMV-infected
telomerized human foreskin fibroblast (THFs) cells stably express-
ing an HA-tagged version of BST2 (THF-HA146) (Fig. 1A). Two
different strains of HCMV were used: the lab-adapted strain
AD169 and the clinical isolate Toledo. BST2-expressing THFs or
control THFs (THF-PCDH) were infected with an MOI of 3, and
the supernatants were harvested at 72 hours post-infection (hpi).
To determine the presence of infectious virus, we added the
supernatant to fresh primary human foreskin fibroblasts (HFFs).
After 8 h, cells were washed, trypsinized and viral infection was
monitored by analysis of viral immediate early gene (IE1)
expression in immunoblot. Unexpectedly, we observed higher
IE1 levels in HFFs exposed to supernatants from BST2-expressing
THF-HA146 cells compared to the supernatant obtained from
control THF-PCDH cells (Fig. 1B). This indicated that there was
an increased amount of infectious virus particles released in the
presence of BST2, which is contrary to the observation of
restricted virus release of other enveloped viruses. To confirm this
observation, we determined the amount of infectious virus released
into the supernatant by plaque assay. We infected two different
HFF-lines expressing BST2 with HA tags at AA positions 110 or
146 (Fig. 1 A). Each of the BST2-expressing HFF-lines, as well as a
control-transfected HFF line, was infected with AD169 at an MOI
of 3. The supernatants were collected 72hpi and the concentration
of HCMV plaque forming units (PFU) was determined by dilution
on HFFs. Compared to the control-transfected HFFs, approxi-
mately five times more PFU were recovered from each of the
BST2 expressing cells (Fig. 1C). Thus, infectious virus released in
the supernatant increased in the presence of BST2 irrespective of
the position of the HA tag.
To determine whether increased presence of virus in the
supernatant was due to increased infection of the BST2-expressing
fibroblasts or increased infectivity of released virus we knocked
down BST2 in THF-HA146 and HFF-HA146 cells using a
previously described siRNA [14] prior to infection with AD169-
GFP (MOI=1). The number of infected cells was monitored by
flow-cytometry for GFP. At 24 hpi the cells were harvested and the
number of GFP-positive cells was determined. The results showed
that inhibiting BST2 expression reduced the number of GFP-
positive cells whereas knockdown of the cellular protein GAPDH or
control siRNA had no effect (Fig. 1D). Furthermore, BST2 siRNA
didnotaffectthe number of GFP-positive cellsincontrol fibroblasts.
Thus, BST2 enhanced an early event in the viral life cycle rather
than promoting egress or infectivity of released virus.
Since these data suggested that early or immediate early events
were modulated by BST2 we compared the expression of the viral
immediate early gene 1 (IE1) in BST2-expressing THFs to control
THFs or HFFs by immunoblot. For control of host cell gene
expression and as loading control we included immunoblots for
GAPDH. Furthermore, we treated each cell line with control
siRNA (siGLO) or with siRNA to BST2 prior to infection with the
HCMV strain Toledo. As shown in Fig. 1E, there was a significant
increase of IE1 protein recovered from BST2-expressing THFs
compared to both HFF and THF. In contrast, targeted
knockdown of BST2, but not of GAPDH or control siRNA
treated cells, reduced the levels of IE1 expression in the BST2-
transfectants but not in the control cells (Fig. 1E, F). Taken
together these data demonstrate that BST2 expression increased
viral infection of fibroblasts and that this increase of infection was
responsible for increased virus production of these cells.
BST2 enhances virus entry
Since BST2 is a protein that recycles between the cell surface
and intracellular compartments [25] it was conceivable that
enhanced infection of BST2-expressing fibroblasts was caused by
BST2 enhancing viral entry. Upon fusion of herpes virions with
plasma or endosomal membranes, proteins of the viral tegument, a
protein-rich compartment layered between the capsid and the
envelope, are released into the cytoplasm together with the viral
capsid [29]. Therefore, we determined the amount of the major
tegument proteins pp71 and pp65 recovered from BST2-
expressing or control THFs immediately after virus infection and
prior to onset of immediate early gene expression. Additionally, we
monitored the amount of viral genomes present in cells by qPCR.
THF-PCDH and THF-HA146 cells were infected with AD169
(MOI=3) for 2 h at 37uC, and then the cells were washed with
citric acid buffer (pH=3) to remove adhered virions from the cell
Author Summary
Human Cytomegalovirus (HCMV) persistently infects a
large proportion of the human population without causing
any symptoms. The establishment and maintenance of
HCMV in infected individuals is thought to be facilitated by
the ability of HCMV to modulate innate and adaptive
immune responses by the host. BST2, aka Tetherin, was
recently shown to be an innate immune response
molecule that is induced by the antiviral cytokine
interferon. BST2 has been shown to prevent the release
of many different viruses, including the human immuno-
deficiency virus and Ebola virus, from infected cells by
tethering the viral envelope to the host cell membrane.
Unexpectedly however, we observed that BST2 had the
opposite effect on infection by HCMV. Cells expressing
BST2 became more susceptible to infection with HCMV.
Thus, HCMV seems to use this antiviral protein to gain
access to cells that naturally express high levels of BST2
such as macrophages.
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DNA by qPCR (Fig. 2A) or the tegument protein pp71 by
immunoblot (Fig. 2B). At 2hpi, BST2-expressing cells contained an
increased amount of viral genome copies as well as tegument
protein pp71 (Fig. 2A, 2B). In contrast, when BST2 expression was
decreased by siRNA in THF-HA146 (Fig. 2D), reduced amounts
of genomic DNA (Fig. 2C) and tegument protein pp65 (Fig. 2E)
was recovered. These results are consistent with viral entry being
increased in the presence of BST2. To rule out that increased
tegument proteins were due to increased viral gene expression we
exposed cells to UV-inactivated AD169 which is still able to attach
to and enter cells but unable to express viral genes. Similar to
infection with untreated virus, increased amounts of pp71 were
recovered from THF-HA146 infected with UV-inactivated virus
as compared to THF-PCDH (Fig. 2B), whereas BST2 knockdown
decreased recovery of pp65 from THF-HA146 infected with UV-
inactivated HCMV (Fig. 2E).
Modulation of IFN-dependent and IFN-independent BST2
induction by HCMV
HCMV induces interferon (IFN) and IFN-stimulated genes
(ISGs), but it is also known to interfere with IFN-dependent, JAK/
Figure 1. BST2/Tetherin enhances HCMV infection and release. A) A schematic representation of the BST2 constructs used in this study. B)
Immunoblot for HCMV-IE1 or GAPDH of HFFs exposed to supernatants of HCMV-infected THFs expressing BST2-HA146 or vector control.
Supernatants were obtained after infection with HCMV strains AD169 or Toledo (MOI=3) for 72 hrs. C) Viral titers in supernatants of AD169-infected
HFFs stably expressing the indicated BST2 constructs. Virus was titrated by end point serial dilution assay. D) Percentage of GFP positive cells of THF-
HA146, THF-PCDH, HFF-HA146 and HFF-PCDH cells transfected with the indicated siRNAs 72 hours prior to infection with AD169-GFP for 24 h. GFP
levels in GAPDH controls were set to 100%. E) Immunoblot for IE1 and GAPDH in HFFs, THFs and THF-HA146 cells transfected with the indicated
siRNA 72 h prior to infection with HCMV Toledo for 8 h. F) Immunoblot for IE1, BST2 and GAPDH in HFF-HA146 cells transfected with indicated
siRNAs prior to infection with HCMV AD169 at the indicated MOI for 8 h. For control 40 nM silencer negative control (Ambion) was used. The
numbers below the blots in E) and F) show the relative IE1 band intensity compared to GAPDH (using ImageJ) normalized to control siRNA.
doi:10.1371/journal.ppat.1002332.g001
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IFN we were wondering whether HCMV would modulate IFN-
independent and IFN-dependent BST2 gene induction during
infection. Non-transfected HFFs express low but detectable
amounts of BST2 constitutively and BST2 levels can be strongly
induced by IFN, as expected (Fig. 3A). Interestingly, induction of
BST2 was also observed upon HCMV-infection. Moreover, UV-
inactivated HCMV induced BST2 to a much higher level than live
HCMV. However, when HFFs were simultaneously treated with
IFN and infected with HCMV, HCMV suppressed BST2
expression (Fig. 3A). These results are consistent with the
previously reported IRF3-dependent induction of IFN and ISGs
by both live and UV-inactivated HCMV [30] whereas IFN-
dependent, JAK/STAT-mediated ISG induction is inhibited by
live but not UV-inactivated HCMV [32]. This conclusion was
further supported when BST2mRNA expression levels were
measured by qPCR. Live HCMV induced BST2 mRNA to a
lesser degree than UV-inactivated HCMV (Fig. 4B) and BST2
mRNA levels were strongly increased upon IFN treatment.
Infection with HCMV reduced this induction (Fig. 4B). Thus,
although HCMV interferes with IFN-dependent BST2 gene
induction, most likely due to its known interference with JAK/
STAT signaling, HCMV induces BST2 mRNA and does not seem
to interfere with BST2 protein expression at a post-transcriptional
level, in marked contrast to HIV-1 and KSHV. This conclusion is
also supported by the fact that HCMV does not downregulate
Figure 2. BST2/Tetherin enhances HCMV entry into fibroblasts. A) Relative viral genome copies were quantified using Taqman probes in the
BST2-expressing or control THFs exposed to HCMV AD169 (MOI=2) at 37uC for 90 min followed by a citric acid (pH=3) wash. B) Immunoblot for
pp71, BST2 and GAPDH of BST2-expressing or control THFs exposed to live or UV-inactivated HCMV-AD169 (MOI=2) at 37uC for 90 min followed by a
citric acid (pH=3) wash. Band intensities of pp71 were compared to GAPDH. C) Relative viral genome copies were measured in BST2 expressing THF-
HA146 cells treated with the indicated siRNAs for 72 h prior to infection with HCMV for 90 min. Infection conditions were as in A). D) In parallel
cultures, mean fluorescent intensity levels of surface expression of BST2 was determined by flow cytometry for siRNA treated HA146-BST2 transfected
THFs. E) In a similar experiment as in C) the cells were treated with indicated siRNAs prior to infection with live or UV-inactivated HCMV AD169 (MOI-
2). The level of tegument protein pp65 was analyzed by immunoblot compared to GAPDH.
doi:10.1371/journal.ppat.1002332.g002
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HCMV egress, or HCMV counteracts BST2 in a way that does
not affect BST2 protein levels or surface expression.
BST2 enhances HCMV entry into non-permissive 293 cells
To determine whether the entry-enhancing effect of BST2 is
limited to fibroblasts, we examined HCMV entry into BST2-
expressing HEK293M cells. Unlike HFFs, these cells are not
permissive for viral replication and therefore could delineate the
role of BST2 in the early events of viral entry versus the later
events of viral replication. We generated stable 293 M cells
expressing BST2 (Fig. 4A) and infected these or control cells with
HCMV-AD169. Viral entry and infection was monitored by
immunoblot for pp71 and IE1 as described above. As shown in
Fig. 4, compared to 293 M-PCDH control, 293 M-BST2HA cells
contained increased amounts of pp71 at 3hpi and IE expression at
24hpi. These results demonstrate that BST2 enhances viral entry
independently of cell type and might even contribute to cell
tropism.
BST2 enhances HCMV infection in activated monocytes
Most somatic cells express low levels of BST2 unless exposed to
IFN. However, BST2 is upregulated during the differentiation of
cells in the hematopoietic lineage leading to constitutive high level
of expression in B cells, T cells, NK cells, and monocyte/
macrophages [10,11]. Particularly pronounced is the expression of
BST2 on plasmacytoid dendritic cells which are major IFN
producers [11]. Among these cell types, monocytes are thought to
be particularly important for HCMV latency, reactivation and
dissemination in vivo [33–34]. Therefore, we explored whether
endogenous BST2 expressed by monocytes would facilitate entry
of HCMV into this cell type. In vitro, HCMV is known to infect
differentiated monocytes preferably over monocyte precursors
[35]. This preference can be recapitulated in the pro-monocytic
cell line THP-1 which can be differentiated into a monocytic cell
type by treatment with phorbol meristate acetate (PMA), and
PMA-induced differentiation correlates with increased infection by
HCMV [36]. Interestingly, surface levels of BST2 drastically
increased upon PMA treatment of THP-1 cells (Fig. 5A, B). It was
previously shown that PMA-treatment of THP-1 cells increased
entry of the lab-strain AD169 [36] although only clinical isolates
are able to replicate productively in this cell type [37]. Indeed, we
observed increased IE1 expression in PMA treated THP-1 cells
compared to untreated cells upon infection with AD169 (Fig. 5B).
AD169-infection of THP-1 cells induced endogenous BST-2
(Fig. 5B) consistent with the increase of BST-2 observed in
AD169-infected fibroblasts (Fig. 3). These data indicated a
correlation between PMA-dependent AD169 infection of THP-1
cells and BST2 levels. To determine whether there was a causative
relationship between AD169 entry and BST2 levels we knocked
down BST2 mRNA levels with siRNA prior to PMA treatment
and HCMV infection. THP-1 cells transfected with control
siRNAs or BST2 siRNA were treated with PMA and entry of
AD169 was monitored for IE1 expression by immunoblot and
IFA. As shown in Fig. 5C, IE1 expression was strongly reduced
upon BST2 siRNA treatment, whereas reduction of GAPDH or
transfection of control siRNA did not have a significant effect.
Interestingly, residual IE1 expression in BST2 siRNA-treated cells
correlated with residual BST2 expression presumably due to
incomplete knockdown in some cells (Fig. 5F). To determine
whether BST2 siRNA also reduced entry of endothelial cell and
macrophage-tropic clinical isolates, we infected PMA-induced
THP-1 cells with the clinical strain HCMV-TR. Compared to
control siRNA treated cells, reduced amounts of viral genome
copies were recovered from THP-1 cells treated with BST2-
specific siRNAs (Fig. 5G). Taken together these data suggest that
induction of endogenous BST2 during monocyte differentiation
facilitates HCMV entry.
Significant surface levels of BST2 were also observed on
primary human monocytes isolated from peripheral blood
mononuclear cells (PBMC) (Fig. 6A). To determine whether
BST2 facilitated HCMV entry into such primary cells, we knocked
Figure 3. HCMV induces BST2 independent of IFN, but inhibits IFN-dependent induction. A) Expression of BST2 monitored by flow
cytometry using anti-BST2 (HM1.24) antibody is shown in all panels except for the shaded graph in the top left panel that shows staining of
secondary antibody alone. Lower panels: Uninfected or HCMV-infected HFFs treated with 500 U of IFNb for 24 hrs. Right Panels: HFFs infected with
indicated viruses (MOI=3) for 24 hrs. The levels of BST2 are graphically represented below. B) Left panel: qPCR of BST2 mRNA in HFFs treated with
500 U of IFNb over indicated times. Middle panel: qPCR of BST2 mRNA in HFFs treated with 500 U of IFNb (two independent experiments) for
24 hours or simultaneously infected with HCMV-AD169 (MOI=3) for the same amount of time. Right panel: qPCR of BST2 upon infection of HFFs with
live or UV-inactivated AD169. C) Flow cytometry of BST2-HA146-expressing THFs uninfected or infected with HCMV-AD169 using anti-HA antibody.
doi:10.1371/journal.ppat.1002332.g003
Figure 4. BST2 increases HCMV infection in 293 M cells. A)
Surface levels of BST2-HA146 in stably transfected 293 M cells were
monitored by flow cytometry with anti-HA. B) Immunoblot of
untransfected or BST2HA-transfected 293 M cells infected with AD169
(MOI=3) and probed for the expression of the tegument protein pp71
or GAPDH at 3hpi after citrate buffer wash. C) Immunoblot for IE1
protein at 24hpi. Relative band intensities are shown to the right of the
blots.
doi:10.1371/journal.ppat.1002332.g004
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PLoS Pathogens | www.plospathogens.org 6 November 2011 | Volume 7 | Issue 11 | e1002332Figure 5. Infection of THP-1 cells with HCMV is BST2-dependent. A) Surface levels of endogenous BST2 upon treatment of THP-1 cells with
PMA for 24 hours (left panel) and immunoblot for total BST2 present upon PMA induction (right panel) . B) FACS and immunoblot analysis of THP-1
cells treated with PMA and upon infection with HCMV-AD169. C) IFA of IE1 in PMA-differentiated THP-1 cells treated with indicated siRNAs and
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monocytes and monitored pp65 (Fig. 6B) or IE1 expression
(Fig. 6C) upon infection with HCMV-strain Toledo. Successful
knockdown of BST2 was verified by immunoblot (Fig. 6B, C). The
experiments were repeated with monocytes from five different
donors. We observed a reduced recovery of pp65 (Fig. 6B) and
reduced expression of IE1 (Fig. 6C) in BST2-siRNA treated cells,
but not in control siRNA treated cells. Therefore, we conclude
that BST2 enhances viral entry into primary human monocytes.
BST2 is present in HCMV virions
Taken together, above experiments suggest that increased BST2
levels enhance HCMV entry and that this facilitated entry might
play an important role in HCMV infection of monocytes. What
might be the molecular mechanism by which BST2 enhances
entry of viral particles into cells? Given our current knowledge of
BST2 as an anti-viral protein that tethers virions to cell
membranes, it is conceivable that BST2 increases HCMV entry
by a similar tethering mechanism except that here the tether is
used to capture HCMV rather than to prevent its release. In the
case of HIV-1 it is thought that BST2 needs to be present in both
the plasma membrane and the virion and that BST2 prevents
budding either by bridging the virion with the membrane or by
BST2 forming homo-dimers or –multimers between virion-
associated BST2 and BST2 in the host cell membrane. Thus, a
prerequisite for the formation of a tether between HCMV and the
plasma membrane would be the presence of BST2 in HCMV
virions. To determine whether BST2 was present in HCMV
particles we fractionated virion preparations via a Nycodenz
gradient to separate contaminating cellular membrane fragments
and defective viral particles from intact, infectious virions. We
tested the concentration of DNA in each of the fractions and
detected representative viral and cellular proteins by immunoblot.
The DNA concentration was measured with 260/280 nm
absorption values and the highest concentration was measured
in fractions 9–12 peaking in fraction 11 (Fig. 7A). This correlated
with the presence of infectious virus in fractions 8–13 as detected
by immunoblot of IE-1 in fibroblasts inoculated with each fraction
(Fig. 7B). The same fractions, particularly fraction 11, also
contained the highest concentration of the virion proteins pp65
and pp28. In contrast, the cellular transmembrane protein CD81
was only found in lower fractions expected to contain contami-
nating membranes. To detect BST2 the sample was de-
glycosylated using PNGaseF and the blot was probed with rabbit
polyclonal anti-BST2. The result showed that BST2 was present in
early fractions and reappeared in the fractions 9–11 that contained
infectious virus (Fig. 7C). Another cellular protein, GAPDH that
was identified by a proteomics study to be present in the virion
[38], showed a similar pattern of distribution like BST2 in the
gradient, where it was detected in early fractions and reappeared
in the later fractions containing live virus. To independently
determine the presence of BST2 in the virion membrane we
analyzed virion preparations by immune electron microscopy with
BST2-specific antibodies using gold-conjugated secondary anti-
bodies. The virus preparation was not permeabilized so that
antibodies would only recognize proteins at the surface of the viral
envelope. For control, we used the viral envelope protein gB. As
shown in Fig. 7D and E, both gB and BST2 were detected on
virions. These observations demonstrate that BST2 is present in
the virus particle.
Discussion
In this study we addressed the question whether the b-
herpesvirus HCMV is affected by the innate immune response
protein bone marrow stromal cell antigen 2 (BST2/HM1.24/
CD317/Tetherin), a protein that has been shown previously to
restrict the release of a number of unrelated enveloped viruses
[19]. Contrary to our expectations, we observed that BST2 is not
only incapable of restricting HCMV from egress but it is, in fact,
utilized by the virus to gain entry into BST2-expressing cells.
Importantly, BST2 facilitated entry of HCMV into hematopoietic
cells which are important in the hematogenous dissemination of
the virus.
In several previously reported instances, the effect of BST2 can
only be observed when viral counter mechanisms are inactivated,
e.g. due to genetic deletion of Vpu from HIV-1 or by siRNA
treatment against K5 of KSHV [14,17]. Thus, our observation
that BST2 did not inhibit the egress of HCMV could indicate that
HCMV developed effective countermeasures. However, while we
observed that HCMV counteracted the IFN-dependent induction
of BST2, presumably as a result of interfering with JAK/STAT
signaling, we observed that HCMV actually induced BST2 upon
infection of fibroblasts. Induction of BST2 is likely due to the viral
activation of IRF3 via the DNA sensor ZBP-1 which results in
induction of IFN and IFN-independent ISG induction [39]. These
observations suggest that HCMV does not eliminate BST2 as
reported for HIV-1 or KSHV [14,17]. However, we cannot rule
out with certainty that HCMV counteracts the antiviral function
of BST2 in a more subtle manner during egress. It is also possible
that BST2 is unable to prevent HCMV egress due to differences
between cytomegaloviral release and that of viruses susceptible to
BST2. In either case, one of the consequences of BST2
upregulation by HCMV seems to be the incorporation of BST2
into the viral envelope. Whether this is a passive incorporation due
to the fact that viral envelopes are derived from cellular
membranes or due to an active enrichment of BST2 into the
viral envelope is currently unknown. Since a previous proteomics
study of HCMV virions did not find BST2 in the virion
preparations [38] it is possible that BST2 levels vary between
virus preparations. Alternatively, the abundance of BST2 was too
low to be detected by mass-spectrometry.
In contrast to other enveloped viruses, we observed that BST2
increased HCMV infection. This increase was observed consis-
tently with two viral strains in different cell types using different
BST2 construct as well as upon induction of endogenous BST2.
Since this increased infection was observed prior to the onset of
viral gene expression and even when virus was UV-inactivated, we
concluded that BST2 enhanced viral entry. BST2 is highly
expressed on monocytes, monocyte-derived macrophages and
dendritic cells. Therefore, we propose that BST2 facilitates entry
infected with HCMV-AD169 for 24 h. Representative fields are shown as 106 magnified frames. D) IE1 positive-cells and DAPI-positive cells were
counted from 5 fields using Image J (http://rsbweb.nih.gov/ij/). The average ratio of infected versus total number of cells is shown. E) IE1-immunoblot
analysis of a similar experiment as in C. GAPDH-normalized band intensities are given below the bands. The efficiency of BST2 knock down is
represented as mean fluorescence intensity of BST2 on the cell surface by flow cytometry analysis. F) IFA of HCMV-infected THP-1 cells treated with
low amounts of BST2-siRNA resulting in residual cells expressing BST2. At 24 hpi the cells were probed for BST2, IE1 and DAPI. G) Relative genome
copies of HCMV TR at 90 min post-infection of PMA activated THP-1 cells treated with indicated SiRNAs for 72 h. To remove extracellular virus, cells
were washed with citric acid buffer (pH=3) prior to harvesting.
doi:10.1371/journal.ppat.1002332.g005
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monocytes support this. However, the presence of BST2 is not
sufficient for HCMV infection of other BST2-expressing cell types
such as T cells and B cells, because HCMV replication can be also
restricted post-entry (as observed for AD169 in THP-1 cells).
Thus, unlike a bona-fide receptor, BST2 is not essential for infection
because viral infection also occurs in the absence of BST2,
particularly in fibroblasts. Instead BST2 seems to act as a co-
factor, or co-receptor that facilitates but is not essential for viral
entry. In the presence of BST2 a larger percentage of cells seem to
be infected rather than an increase of viral replication in individual
cells. Therefore, it is conceivable that BST2 increases viral
dissemination in vivo by gaining increased access to BST2-
expressing cells.
At present, it is unclear how BST2 increases viral entry.
However, based on the known function of BST2 as a viral tether
preventing viral budding it is conceivable that a similar but reverse
mechanism could operate during entry. Interestingly, a report by
Figure 6. BST2 facilitates HCMV entry into primary human monocytes. A) BST2 expression on adherent monocytes isolated from PBMCs was
analyzed by flow cytometry. B) Immunoblot of pp65, BST2 or GAPDH upon treatment of human monocytes with the indicated siRNAs. C) IE1, BST2 or
GAPDH expression monitored by immunoblot of human monocytes transfected with the indicated siRNAs. Relative intensities (measured using
ImageJ) normalized to GAPDH, from immunoblots of monocytes derived from five different donors are shown to the right in B) and C). Error bars
indicate Mean 6 SD. A p value of ,0.05 was considered significant.
doi:10.1371/journal.ppat.1002332.g006
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topology of BST2 rather than its primary structure is sufficient for
binding and restricting viral release. Thus, replacing the N-
terminal transmembrane domain, the extracellular coiled-coil
motif and the C-terminal GPI anchor with similar domains from
unrelated proteins resulted in a virus-inhibitory protein [40].
Based on these observations, it is hypothesized that BST2 either
tethers budding viruses by linking the envelope with the
membrane through each of its membrane domains or through
dimers that form between virion-associated BST2 and BST2 in the
cell membrane. Indeed, electron micrograph analysis revealed
BST2 in virion junctures and in the membranes of concatenated
virions consistent with either model [40]. Based on these models,
we hypothesize that similar tethering mechanisms by BST2
enhance entry of HCMV. Either virion-associated BST2 interacts
with BST2 at the cell surface or plasma-membrane-associated
BST2 inserts one of its membrane domains into the envelope of
the incoming virus, e.g. during membrane fusion. In both cases,
BST2 at the cell surface will enhance the virion binding and entry
of viruses into the host cells and thereby infection by virus.
Although BST2 is a self interacting protein, BST2 has also been
shown to interact with the cellular protein Immunoglobulin-like
transcript 7 (ILT-7) at the surface of plasmacytoid dendritic cells
[12]. Thus, another potential mechanism for BST2 facilitated
entry could be that HCMV encodes a protein that is expressed in
the virion membrane and mimics ILT-7 allowing interaction with
BST2 on the surface of the target cell. Interestingly, HCMV
expresses UL18, an MHC-I like protein that interacts with ILT-2
a protein of the same family as ILT-7 [41].
In summary, our data suggest an unprecedented and unexpect-
ed role for BST2 in HCMV entry. This observation is in stark
contrast to the well-established role of BST2 in prohibiting egress
of a number of unrelated viral families, including at least one
herpesvirus [14]. In particular, lentiviruses seem to be highly
sensitive to inhibition by BST2 as indicated by the observation that
primate lentiviruses generally counteract BST2 of their host
Figure 7. BST2 is present in HCMV virions. A) HCMV preparations were separated by a discontinuous (5–50%) Nycodenz gradient and equal-
sized fractions were isolated prior to spectrophotometric analysis of total DNA. B) Immunoblot for IE1 or GAPDH of HFFs infected with each of the
fractions. C) Fractions were probed for the viral proteins gB, pp65 and the cellular proteins BST2 (PNGaseF treated), CD81 and GAPDH by
immunoblot. D) Immunoelectron microscopy analysis of purified virions for BST2 and HCMV gB. 20 nm gold conjugated secondary antibody was
used to detect BST2 and gB. E) Percentage of immunogold positive virions counted from multiple plates for each treatment.
doi:10.1371/journal.ppat.1002332.g007
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primate species [23]. In contrast, CMV appears to employ BST2
as an entry factor. Since CMVs co-evolve with their hosts, each
CMV strain may adapt to the BST2 of the host species. In vivo,
BST2-mediated enhancement of HCMV entry may play a
particularly important role in macrophages and dendritic cell that
express BST2 upon differentiation in response to infection and
inflammation. In addition high levels of BST2 expression have
been observed on many cancer cell lines [42] which correlates with
reports of high levels of CMV antigen in certain tumors [43].
Thus, BST2 may contribute to CMV tissue tropism. Further
studies will delineate these possibilities.
Materials and Methods
Ethics statement
Healthy human volunteers who donated blood provided
informed written consent before signing research authorization
forms that complied with the US Health Insurance Portability and
Accountability Act in addition to a medical history questionnaire.
These studies were approved by the Institutional Review Board of
OHSU.
Virus and cell culture
Primary human foreskin fibroblast (HFF) cells were obtained
from ATCC and cultured in Dulbecco’s minimal essential medium
(DMEM) supplemented with 10% fetal bovine serum, L-
Glutamine and 100 units of penicillin/streptomycin in a
humidified incubator with 5% CO2 at 37uC. HFF cells used in
this study were between passages 8 and 20. HFFs stably
transfected with the human telomerase gene (THFs) to extend
passage life were obtained from W. Bresnahan (University of
Minnesota) [44]. THFs were propagated the same way as HFFs.
THP-1 cells were cultured in RPMI with L-Glut, 10% FBS and
100 units of penicillin/streptomycin. HCMV strain AD169 was
obtained from the ATCC and Toledo from in house stocks. The
viruses were propagated in primary HFFs and purified by
centrifugation through a 20% sorbitol cushion for 1 h at
22,000 rpm in a Beckman SW28 rotor. The titers of virus stocks
were determined using endpoint serial dilution assays on primary
HFFs. For pure virus preparations the supernatant collected from
infected cells was cleared of whole cell by spinning at 1,500 rpm,
4uC for 5 min, then the membrane contaminants were removed
by two spins at 7,500 rpm, 4uC, 15 min followed by sorbitol
cushion purification. This partially cleaned virus was subjected to
Nycodenz gradient (50-5% in TNE buffer - 50 mM Tris [pH 7.4],
100 mM NaCl, and 10 mM EDTA). Fractions of the separated
gradient were spun at 30,000 rpm at 4uC for 1 h followed by a
wash with PBS. The isolated fractions were tested for the presence
of viral and cellular proteins, DNA concentration and infectivity.
Inactivation of HCMV particles using UV irradiation was
performed in a Stratalinker for a length of time sufficient to block
expression of protein from the HCMV open reading frame UL123
(IE1) and to induce MHC-I expression as result of IFN activation
in the treated cells. Histodenz (Nycodenz) was purchased from
Sigma Aldrich.
Reagents and antibodies
The antibodies pp65, gB (HCMV), CD81 and GAPDH were
purchased from Santa Cruz biotechnologies. BST2 rabbit
polyclonal antibody was obtained through the AIDS Research
and Reference Reagent Program, Division of AIDS, NIAID, NIH
from Drs. Klaus Strebel and Amy Andrew (https://www.
aidsreagent.org/index.cfm). Anti-HA antibody was obtained from
Covance Inc., and the IE1 antibody was from Light Diagnostics.
Antibody to pp71 was a gift from Dr Thomas Shenk [45]. Human
recombinant IFNb was obtained from PBL Interferon Source,
Piscataway, NJ.
BST2 expressing stable fibroblasts
Human bst-2 cDNA was amplified as an NheI/BamHI
fragment by a PCR using the Pfu enzyme (Stratagene, San Diego,
CA) and inserted into the lentiviral vector pCDH-CMV-
MCSEF1-Puro (System Biosciences, Mountain View, CA). BST2
and its mutants with a hemagglutinin (HA) tag at position 146
(BST2-HA146) and position 110 (BST2-HA11) were generated by
primer-directed mutagenesis using PCR as previously described
[14]. Lentiviral supernatants were produced via triple transfection
of 293T cells with the pHP-dl-N/A packaging construct, the
pHEF-VSVG envelope construct (both constructs were obtained
through the AIDS Research and Reference Reagent Program,
Division of AIDS, NIAID, NIH, from Lung-Ji Chang), and one of
the lentiviral clones described above. Transfections were per-
formed using Effectene (Qiagen, Germantown, MD), with a
plasmid ratio of 6:1:3 (packaging construct:envelope construct:le-
ntiviral clone). After 48 h, the supernatants were collected, and
lentiviruses were purified through a 0.8 mm filter. Stable cell lines
expressing the previously described constructs BST2HA146 and
BST2HA110 [14] were generated by lentiviral transduction and
puromycin selection (0.3 mg/ml) in THFs and HFFs. Cells
transfected with empty pCDH vector were generated for control.
PBMC-derived monocyte isolation and activation
Isolation of human peripheral blood monocytes was performed
as previously described [33]. Briefly, blood was drawn by
venipuncture and centrifuged through a Ficol Histopaque 1077
gradient (Sigma-Aldrich, St. Louis, MO) at 2006g for 30 min at
room temperature (RT). Mononuclear cells were collected and
washed twice with PBS and 1 mM EDTA to remove platelets at
1506g for 10 min at RT. Monocytes were then layered on top of
a 45% and 52.5% iso-osmotic Percoll gradient and centrifuged for
30 min at 4006g at RT yielding monocyte population that was
more than .90% pure. Cells were washed twice with saline at
1506 g for 10 min at RT to remove residual Percoll and
suspended in RPMI 1640 (Cellgro) supplemented with 10%
human serum (Sigma-Aldrich).
Virus infection
To monitor virus entry, HCMV was added to cells at an MOI
of 3 unless otherwise noted and rocked in an incubator with CO2
at 37uC for 1 h. Then the cells were washed with citric acid buffer
(pH=3) followed by three cold PBS washes and lysed in Laemmli
buffer with 10% b-mercaptoethanol. The lysates were analyzed for
the expression of tegument proteins pp65 or pp71 using previously
described antibodies. For analysis of immediate early gene
expression infected cells were harvested 8hpi and lysates subjected
to immunoblot. For the time course analysis with AD169-GFP
virus, the cells were treated with the virus at an MOI of 2 and
analyzed for GFP positive cells over time. SiRNA treatment was
performed 2 days prior to cell infection with AD169-GFP at MOI
of 1 and analyzed for GFP positive cells 24hpi. THP-1 cells and
293-M cells were infected with HCMV-AD169 at an MOI of 3
and harvested at early times (3 h) to detect tegument proteins or at
a later times (24 h) for analysis of IE1 protein expression. PBMC
derived monocytes were infected with HCMV Toledo at an MOI
of 5. Relative genome copies were measured in THP-1 cells
activated using PMA and infected with HCMV-TR strain after
SiRNA treatments.
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SiRNA against BST2, GAPDH and SiGlo were obtained from
Dharmacon Inc., Lafayette, CO (Smart pool) and negative control
siRNAs (-ve SiRNA) from Qiagen. HFF cells were treated with
Lipofectamine 2000 (3 mL/mL; Invitrogen) and SiRNAs at a
concentration between 10–40 nM twice 72 h apart. THP-1 cells
were treated with Hyperfect (10 mL/mL; Invitrogen) and SiRNA
at 40 nM after 24 h of treatment with PMA (1 mg/mL). PBMC-
derived monocytes were treated with RNAi Max (10 mL/mL;
Invitrogen) after adhering to plastic with 50 nM of the SiRNAs for
48 h and infected with HCMV for 4 h or 24 h. The cells were
probed for pp65 or IE1 proteins.
Immunofluorescence and flow cytometry
THP-1 cells were treated with 1 mg/ml of PMA for 24 h
followed by transfection with SiBST2. After three days, the cells
were infected with HCMV and washed with PBS after 24 hours
followed by fixing with 2% paraformaldehyde and incubating with
antibodies for IE1 and BST2. Slides were fixed a second time in
2% paraformaldehyde after the final antibody treatment and
washed three times with PBS. Coverslips were then mounted on
slides and covered with Vectashield H-1200 DAPI (Vector
Laboratories).
For flow cytometry, cells were removed from tissue culture
dishes with 0.05% trypsin-EDTA (Invitrogen), washed with ice-
cold PBS, and fixed with 3.7% formaldehyde solution. For
intracellular staining, cells were permeabilized using perm wash
solution (1% saponin, 10% NaN3, 10% fetal calf serum [FCS], in
PBS). For surface staining the cells were directly incubated with
appropriate primary antibody for 60 min at 4–8uC. The cells were
washed with ice-cold PBS and either resuspended in ice-cold PBS
or incubated with PE-conjugated anti-mouse secondary antibody
(Dako, http://www.dako.com) and washed twice again before
analyzed using FACSCalibur flow cytometer (BD Biosciences).
Quantitative PCR
Total mRNA from cells was isolated and purified using RNeasy
(Qiagen). Specific primers for BST2 and b-actin were designed
using Primer 3 software (BST2 primers CCGTCCTGCTC-
GGCTTT [forward] and CCGCTCAGAACTGATGAGATCA
[reverse]; b-actin primers - TCACCCACACTGTGCCCATC-
TACGA [forward] and GCGGAACCGCTCATTGCCAATGG
[reverse]). Transcript levels were determined by quantitative real-
time reverse transcriptase PCR (qPCR), using SYBR green dye
incorporation (AB Applied Biosystems, Warrington, United
Kingdom) and AmpliTaq Gold DNA polymerase in an ABI
Prism 7900HT sequence detection system (AB Applied Biosys-
tems, Warrington, United Kingdom). The comparative threshold
cycle method was used to derive the change in gene expression
between different treatments, using b-actin as an internal
standard.
To quantify the number of viral genomes in DNA isolated from
infected cells we used a Taqman primer probe set that amplifies
the UL81/82 region of the HCMV genome (Fwd - GAGG-
TAGGTCGTAGTGCGGC ; Rev- GCTCTCACGCTCGT-
CATCC ; probe: TGCTGCACGCTCAC with VIC reporter).
50 ng of total cellular DNA isolated from infected cells after citric
acid wash was used as template. A standard curve was determined
using DNA isolated from the input virus. The DNA was amplified
on a ABI step one plus and the data were analyzed using step one
software v2.1.
Western blot analysis and quantification
The samples were prepared in Laemmli buffer with 10% b-
mercaptoethanol and separated using 10% SDS-PAGE. The
proteins were transferred to polyvinylidene difluoride membrane
(Waters Ltd., Milford, MA) and probed with primary antibodies
for 1 h at room temperature, followed by horseradish peroxidase-
conjugated secondary antibody (Santa Cruz Antibody Solutions).
Membranes were washed in 0.1% Tween 20 in PBS. The proteins
were detected using a SuperSignal West Femto chemilumines-
cence kit (Thermo Scientific, Rockford, IL). The bands were
quantified using Image J software from NCBI (http://rsbweb.nih.
gov/ij/). The images were converted into the binary mode and
ratios were derived by comparing viral protein band to the host
control protein band (GAPDH) and represented as graphs next to
the blots. For detecting BST2 in virion sample, it was
deglycosylated using PNGaseF (New England biolabs inc.,).
Electron microscopy: Immunogold labeling of gradient
purified HCMV virions
Approximately 10
8 particles were applied to carbon-coated gold
300-mesh grids. The virions were fixed in 4% paraformaldehyde
in PBS and grids were washed three times in PBS, blocked in 5%
BSA, 2% normal goat serum in PBS (pH 7.4) followed by
incubation with antibodies to BST2 or HCMV gB for one hour.
Then the grids were washed and incubated with secondary 20-nm
gold conjugated anti-mouse antibodies (Ted Pella Inc., Redding,
CA) diluted 1:20 in blocking solution. The samples were stained
with ammonium molybdate and examined on a Philips EM 300
electron microscope. For statistical analysis gold positive virus
particles were counted and presented as percentage of total virus
particles.
Statistical analysis
The bar graphs for viral entry assay represent mean 6 SD from
3 to 5 replicates for each experiment. Significance was assessed by
analysis of variance (ANOVA) with secondary Fishers least
significant difference (FLSD) and Mann Whitney; P values,0.05
considered significant.
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